Scil Technology and Pfizer signed an exclusive licensing agreement to develop and commercialize novel cartilage growth factor. by Fabio Ferfoglia, PhD , 21/01/2008
March 21st, 2007, Medtronic Inc announced it had entered into a development agreement with OsteoGenix Incorporated. The agreement would enable OsteoGenix to complete preclinical work on its proprietary bone anabolic agent and advance this program through clinical trials. The agreement would give Medtronic an additional source of bone growth therapies for surgeons whose patients require bone grafting options.
Get the RSS feed you need!